


<PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
        <PMID Version="1">31199180</PMID>
        <DateRevised>
            <Year>2019</Year>
            <Month>06</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1439-7609</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <PubDate>
                        <Year>2019</Year>
                        <Month>Jun</Month>
                        <Day>14</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Modern rheumatology</Title>
                <ISOAbbreviation>Mod Rheumatol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: a subgroup analysis from a Phase 3 randomized placebo-controlled trial.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1-19</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1080/14397595.2019.1630897</ELocationID>
            <Abstract>
                <AbstractText><b>Objectives:</b> To assess the effects of belimumab on disease activity across multiple organ domains in Japanese patients from the Phase 3 randomized, double-blind, North-East Asia study, BEL113750 (NCT01345253). <b>Methods:</b> Patients, aged ≥18 years, with American College of Rheumatology-defined systemic lupus erythematosus (SLE) and a Safety of Estrogen in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI) score ≥8 at screening, on stable SLE treatment, were randomized 2:1 to receive intravenous belimumab 10 mg/kg or placebo, plus standard of care, on Days 0, 14, and 28, then 4-weekly until Week 48. Patients were assessed for SELENA-SLEDAI and British Isles Lupus Assessment Group (BILAG) organ system improvement/worsening between baseline and Week 52. <b>Results:</b> Sixty patients (belimumab, n = 39; placebo, n = 21) were enrolled in Japan. Improvement was seen in a greater proportion of belimumab patients, compared with placebo, in most SELENA-SLEDAI and BILAG domains (significant for the mucocutaneous domain). Worsening occurred in SELENA-SLEDAI hematologic and renal systems (&lt;7% both treatments) and in a number of BILAG systems: &lt;11% (placebo) and &lt;8% (belimumab), although the small sample size should be noted. <b>Conclusions:</b> Organ system improvements were seen in more Japanese belimumab-treated than placebo-treated patients, providing further evidence supporting belimumab use in Japanese patients with SLE.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Tanaka</LastName>
                    <ForeName>Yoshiya</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>a The First Department of Internal Medicine , School of Medicine, University of Occupational and Environmental Health , Kitakyushu , Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bass</LastName>
                    <ForeName>Damon</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Immuno-Inflammation, GSK , Philadelphia , PA , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chu</LastName>
                    <ForeName>Myron</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Immuno-Inflammation, GSK , Philadelphia , PA , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Egginton</LastName>
                    <ForeName>Sally</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>c Biostatistics, GSK , Stevenage , Hertfordshire , UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ji</LastName>
                    <ForeName>Beulah</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>d R&amp;D Clinical Development, GSK , Stockley Park, Uxbridge, Middlesex, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roth</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>b Immuno-Inflammation, GSK , Philadelphia , PA , USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2019</Year>
                <Month>06</Month>
                <Day>14</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Mod Rheumatol</MedlineTA>
            <NlmUniqueID>100959226</NlmUniqueID>
            <ISSNLinking>1439-7595</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">British Isles Lupus Assessment Group (BILAG)</Keyword>
            <Keyword MajorTopicYN="Y">Safety of Estrogen in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI)</Keyword>
            <Keyword MajorTopicYN="Y">belimumab</Keyword>
            <Keyword MajorTopicYN="Y">organ damage</Keyword>
            <Keyword MajorTopicYN="Y">systemic lupus erythematosus</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2019</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>aheadofprint</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">31199180</ArticleId>
            <ArticleId IdType="doi">10.1080/14397595.2019.1630897</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

